SEC Comment Letter for I-Mab (IMAB) (CIK 0001778016) (NBP) — Dec 9, 2020
I-Mab (IMAB) (CIK 0001778016)
Date: Dec. 9, 2020 · CIK: 0001778016 · Accession: 0000000000-20-011813
AI Filing Summary & Sentiment
File numbers found in text: 333-251050
Letter
United States securities and exchange commission logo December 9, 2020 Jielun Zhu Chief Financial Officer I-Mab Suite 802, West Tower, OmniVision 88 Shangke Road, Pudong District Shanghai, 201210 People’s Republic of China Re:I-Mab Registration Statement on Form F-1 Filed December 1, 2020 File No. 333-251050 Dear Mr. Zhu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Deanna Virginio at 202-551-4530 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Z. Julie Gao, Esq.
Show Raw Text
United States securities and exchange commission logo
December 9, 2020
Jielun Zhu
Chief Financial Officer
I-Mab
Suite 802, West Tower, OmniVision
88 Shangke Road, Pudong District
Shanghai, 201210
People’s Republic of China
Re:I-Mab
Registration Statement on Form F-1
Filed December 1, 2020
File No. 333-251050
Dear Mr. Zhu:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Deanna Virginio at 202-551-4530 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Z. Julie Gao, Esq.